Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
The non-peptide CXCR4 receptor antagonist AMD3100, which is a potent blocker of human immunodeficiency virus cell entry, is a symmetrical bicyclam composed of two identical 1,4,8,11-tetraazacyclotetradecane (cyclam) moieties connected by a relatively rigid phenylenebismethylene linker. Based on the known strong propensity of the cyclam moiety to bind carboxylic acid groups, receptor mutagenesis identified Asp(171) and Asp(262), located in transmembrane domain (TM) IV and TM-VI, respectively, at each end of the main ligand-binding crevice of the CXCR4 receptor, as being essential for the ability of AMD3100 to block the binding of the chemokine ligand stromal cell-derived factor (SDF)-1alpha as well as the binding of the receptor antibody 12G5. The free cyclam moiety had no effect on 12G5 binding, but blocked SDF-1alpha binding with an affinity of 3 microm through interaction with Asp(171). The effect on SDF-1alpha binding of a series of bicyclam analogs with variable chemical linkers was found to rely either only on Asp(171), i.e. the bicyclams acted as the isolated cyclam, or on both Asp(171) and Asp(262), i.e. they acted as AMD3100, depending on the length and the chemical nature of the linker between the two cyclam moieties. A positive correlation was found between the dependence of these compounds on Asp(262) for binding and their potency as anti-human immunodeficiency virus agents. It is concluded that AMD3100 acts on the CXCR4 receptor through binding to Asp(171) in TM-IV and Asp(262) in TM-VI with each of its cyclam moieties, and it is suggested that part of its function is associated with a conformational constraint imposed upon the receptor by the connecting phenylenebismethylene linker.
Gerlach
L O
LO
Laboratory for Molecular Pharmacology, University of Copenhagen, Panum Institute, DK-2200 Copenhagen, Denmark.
Skerlj
R T
RT
Bridger
G J
GJ
Schwartz
T W
TW
D000595:Amino Acid Sequence; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001216:Asparagine / Q000737:chemistry; D001224:Aspartic Acid / Q000737:chemistry; D001596:Benzylamines; D001667:Binding, Competitive; D019556:COS Cells; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000737:chemistry; D000080027:Cyclams; D018076:DNA, Complementary / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008024:Ligands; D016014:Linear Models; D008956:Models, Chemical; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding; D011487:Protein Conformation; D019718:Receptors, CXCR4 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D014162:Transfection
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D001596:Benzylamines; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D000080027:Cyclams; D018076:DNA, Complementary; D006571:Heterocyclic Compounds; D008024:Ligands; D019718:Receptors, CXCR4; C024560:cyclam; D001224:Aspartic Acid; D001216:Asparagine; C088327:plerixafor